Wall Street Zen Downgrades Aclarion (NASDAQ:ACON) to Sell

Aclarion (NASDAQ:ACON) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Aclarion Trading Down 0.4%

Shares of NASDAQ ACON opened at $2.58 on Friday. Aclarion has a 12-month low of $2.34 and a 12-month high of $229.50. The company has a market cap of $2.19 million, a PE ratio of -0.17 and a beta of 1.44. The stock has a 50 day simple moving average of $4.58 and a 200-day simple moving average of $6.39.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.